TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06640647
Drug: HDM1005 injection or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HDM1005 injection or placebo isubcutaneous injection once
Study: NCT05247866
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W
Study: NCT05995600
Drug: Antiplatelet Drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel ± other antiplatelet drug
Study: NCT05995600
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
Study: NCT06642987
Drug: Vonoprazan Test 20mg
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1 tablets orally once a day
Study: NCT06642987
Drug: Vonoprazan Reference 20mg
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1 tablets orally once a day
Study: NCT06644937
Drug: TACE combined with Acoradine
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) .
Study: NCT06643208
Drug: TACE-HAIC, Envafolimab and Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
Study: NCT05746273
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study: NCT05579288
Drug: Nitrous oxide (N2O/O2)
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2O/O2) for pain alleviation
Study: NCT05579288
Drug: Oxygen (O2)
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen (O2) as placebo for control group
Study: NCT06196320
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
Study: NCT06196320
Drug: Best Practice (which may include intravenous Alteplase)
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
Study: NCT06468943
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8mg/kg/21d（d0） Intravenous infusion
Study: NCT06468943
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160mg bid PO（d0-d20）
Study: NCT06468943
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/㎡/21d（d0） Intravenous infusion
Study: NCT06468943
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg PO （d1-d5）/21d
Study: NCT05405257
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 1IU Oxytocin in 200 ml 0.9%NaCl over 40 minutes. Total of three infusions in three consecutive days (one per day).
Study: NCT05032352
Drug: Adjuvant
Normalized name: RNADJUVANT
DrugBank: Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine (DB16757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
Study: NCT06117540
Drug: WX390
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: WX390 tablet, 1.1 mg once a day
Study: NCT04562090
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Study: NCT05841771
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation.
Study: NCT05841771
Drug: Azacitidine or decitabine
Normalized name: Decitabine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azacytidine 32mg/m2 or decitabine 5mg/m2
Study: NCT05570318
Drug: Polyethylene Glycols
Normalized name: polyethylene glycols
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
Study: NCT06123468
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
Study: NCT06136884
Drug: AO-252
Normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-252 will be administered oral tablets or capsules daily
Study: NCT06255340
Drug: BI 3031185
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 3031185
Study: NCT06491576
Drug: BGT-002
Normalized name: BGT-DTDS
DrugBank: BGT-DTDS (DB18664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking the study drug orally
Study: NCT06085638
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by SC (under the skin) or IV (vein)
Study: NCT06085638
Drug: Tamibarotene
Normalized name: Tamibarotene
DrugBank: Tamibarotene (DB04942)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT06085638
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax
Study: NCT04380740
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
Study: NCT06253611
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240 mg IV; every 2 weeks
Study: NCT05404919
Drug: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-hepatitis B medications
Study: NCT05212337
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection with 60 mg Denosumab once
Study: NCT05212337
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection with NaCl once
Study: NCT06438250
Drug: 68Ga-JH04
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 148-222 MBq given intravenously.
Study: NCT06489652
Drug: 89Zr-Oxine-RY_SW01 Cell Injection
Normalized name: oxine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
Study: NCT05411900
Drug: BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A vial of 500 units of BoNT-A will be reconstituted with 2 mL of saline solution (0.9%) and 1 mL of lidocaine solution (2%) to obtain a final concentration of BoNT-A of 166.6 units/mL.~Injections will be repeated at sites 1-1.5 cm apart (0.1 ml, 16.6 units per site), up to 20 sites (333 units).~To reduce pain caused by the injection, lidocaine and prilocaine cream will be applied to the skin area 60 min before the procedure. Additionally, ice could be applied for a few seconds (4-8) before each injection of 16.6 units of BoNT-A.~Injections will be repeated at week 0 and week 12.~The active treatment and placebo solutions will be transparent and indistinguishable to maintain treatment blindness.
Study: NCT06635850
Drug: Mosliciguat
Normalized name: Mosliciguat
DrugBank: Mosliciguat (DB19425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1, 2, or 3 for inhalation
Study: NCT06293287
Drug: Subcutaneous enoxaparin sodium
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
Study: NCT06496607
Drug: Biological: Solrikitug Low Dose
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug Low Dose subcutaneous injection
Study: NCT06496607
Drug: Biological: Solrikitug Mid Dose
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug Mid Dose subcutaneous injection
Study: NCT06496607
Drug: Biological: Solrikitug High Dose
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug High Dose subcutaneous injection
Study: NCT03733535
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
Study: NCT03733535
Drug: 129 Xenon
Normalized name: xenon-129
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
Study: NCT06548763
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4mg/㎡, orally administered, d1-5
Study: NCT06548763
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg, intravenous drip, d1, q3w
Study: NCT06461910
Drug: Anti-PD-1 Combined with Thymosin and SOX
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 Combined with Thymosin and SOX in Neoadjuvant Treatment of cStage IIII Gastric or Esophagogastric Junctional Adenocarcinoma
Study: NCT06549400
Drug: Mexiletine granules for prolonged-release oral suspension
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexiletine PR
Study: NCT05533372
Drug: IA-14069
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IA-14069 for oral administration.
Study: NCT05830539
Drug: IN10018+PLD+Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
Study: NCT04913090
Drug: XZP-5610 Tablet (for Part A)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily for 1 Day
Study: NCT04913090
Drug: XZP-5610 Tablet (for Part B)
Normalized name: Amphotericin B for Injection
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily for 14 Days
Study: NCT04913090
Drug: XZP-5610 Tablet for Part C2
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered after a high-fat meal orally once daily for 1 Day
Study: NCT06501352
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Additive to Local anesthetic mixture
Study: NCT06501352
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additive to Local anesthetic mixture
Study: NCT06501352
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control
Study: NCT05052385
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per treating physician's decision - non interventional study
Study: NCT05052385
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As per treating physician's decision - non interventional study
Study: NCT06407544
Drug: PCA device as rescue medication with IV morphine 1mg if VAS more than 4
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA device as rescue medication with IV morphine 1mg if VAS more than 4 with a 10 min lock-out time
Study: NCT04733547
Drug: Furosemide-induced hypovolemia before graft procurement
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is \<1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces \>1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
Study: NCT05018728
Drug: Voxelotor
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
Study: NCT06548971
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
Study: NCT04818229
Drug: CBP-307
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP-307 capsules oral administration.
Study: NCT04818229
Drug: Moxifloxacin (Avelox)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin tablets oral administration。
Study: NCT04818229
Drug: Placebo-matched Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo-matched Moxifloxacin tablets oral administration.
Study: NCT06642623
Drug: Enavogliflozin
Normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Study: NCT06642623
Drug: Dapagliflozin or Empagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Study: NCT05497674
Drug: Rongliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration, single dose on Day 1 and Day 11
Study: NCT05497674
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD for 10 days
Study: NCT05497674
Drug: Rongliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration, single dose on Day 1 and Day 6
Study: NCT05497674
Drug: Probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice a day, for 5 days
Study: NCT05066672
Drug: NV-5138
Normalized name: NV-5138
DrugBank: NV-5138 (DB19180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV-5138 is a novel, orally bioavailable, selective, direct activator of mTORC1 cellular signaling
Study: NCT05933603
Drug: Atomoxetine and Oxybutynin (ato-oxy)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
Study: NCT05392751
Drug: EA-2353
Normalized name: EA-2353
DrugBank: EA-2353 (DB18506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-2353 Ophthalmic Suspension
Study: NCT05767086
Drug: Medroxyprogesterone Acetate (Tarlusal)
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clinical pregnancy rates
Study: NCT05767086
Drug: Dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clinical pregnancy rates
Study: NCT06421311
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: According to approved product label (France)
Study: NCT06305234
Drug: Pegvaliase
Normalized name: PEGVALIASE
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
Study: NCT05029999
Drug: CDX-1140
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
Study: NCT05029999
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
Study: NCT06289062
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
Study: NCT06289062
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
Study: NCT06289062
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
Study: NCT04737603
Drug: ED-Initiated treatment with buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
Study: NCT04903093
Drug: Abrocitinib tablet
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.